Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.
Equillium has raised $35.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
Equillium's investors include RA Capital Management, Alumni Ventures, Janus Henderson Investors, Adage Capital Management, Decheng Capital.
Equillium is headquartered in La Jolla, United States.
Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.
Equillium is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Equillium — Funding & Investors." VCBacked, March 13, 2026, https://www.vcbacked.co/company/equillium. Accessed July 19, 2026.
VCBacked. (2026). Equillium — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/equillium
{{cite web |title=Equillium — Funding & Investors |url=https://www.vcbacked.co/company/equillium |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated